RESEARCH MONOGRAPH · KDC-MN-306

Vincamine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

57/100

Vinpocetine's natural parent alkaloid, almost always the worse pick now but historically important

Vincamine is the periwinkle (Vinca minor) alkaloid that vinpocetine was developed from in the 60s. Most of what vinpocetine does, vincamine does too, just less efficiently. The bioavailability is worse, the half-life is shorter, and the cerebrovascular pharmacology is mechanistically similar but produces a smaller and less reproducible effect. So the historical question of why anyone developed vinpocetine has a clear answer: vincamine had real pharmacology but it needed engineering to be a useful drug.

The mechanism overlap is substantial. Both compounds produce cerebrovascular vasodilation, both have PDE1 inhibitory activity (vinpocetine somewhat more potent), and both have a hint of sodium channel effects in neurons. Vincamine has been used clinically in Europe for cerebrovascular and cognitive indications since the 50s, predominantly as the tartrate or hydrochloride salt, and the clinical experience is genuinely long.

What's interesting historically is that vincamine was one of the first molecules to be characterized as selectively cerebrovascular without significant peripheral vasodilation, which made it useful in a clinical context where you wanted to improve brain perfusion in elderly patients without dropping their systemic blood pressure. That's the lineage that vinpocetine, nicergoline, and the other ergoloid derivatives all draw from.

What we like: well-characterized natural product, defensible historical pharmacology, and a useful reference compound for vincamine-derivative research where you want to compare against the parent alkaloid. The structure-activity work that took vincamine to vinpocetine is a good case study in alkaloid medicinal chemistry.

What we dont love is that there's very little reason to use vincamine instead of vinpocetine for any modern research application. The improvements vinpocetine brings (pharmacokinetics, potency, formulation behavior) are real and the parent compound doesnt have a meaningful clinical or research niche of its own anymore. Most contemporary nootropic literature treats vincamine as a historical reference rather than an active research tool.

Sourcing is okay. Vincamine is extracted from periwinkle or synthesized, well-characterized, and reliable research-grade material is available. HPLC purity is verifiable and the stereochemistry QC (multiple chiral centers, the natural cis-configured material) is the QC item to confirm explicitly. Pharmacopoeia-grade product exists in some European markets.

Evidence: 50
Mechanism: 60
Reliability: 55
Safety: 75
Sourcing: 70
Value: 55
Signal: 45
Staying power: 45

Plain-language summary Intrigue 35 / 100

Vincamine is the natural indole alkaloid extracted from Vinca minor (lesser periwinkle), the parent compound that vinpocetine was derived from. It shares the cerebral-vasodilation and modest phosphodiesterase-inhibition profile with vinpocetine but is shorter-acting and less lipophilic. Approved in France (as Pervincamine) and Italy for cerebrovascular insufficiency and mild dementia. Largely supplanted by vinpocetine in markets where both are available, owing to the latter's better pharmacokinetics. Of mainly historical interest as the natural starting point for the eburnane vasodilator class. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Periwinkle alkaloid / cerebrovascular agent

An indole alkaloid from Vinca minor; the parent compound of vinpocetine, used as a cerebrovascular agent in Europe.

Abstract

Vincamine ((3-alpha,14-beta,16-alpha)-14,15-dihydro-14-hydroxyeburnamenine-14-carboxylic acid methyl ester; CAS 1617-90-9; molecular formula C21H26N2O3; molecular weight 354.45) is an indole alkaloid isolated from Vinca minor (lesser periwinkle). The compound is the natural precursor of vinpocetine, sharing the eburnane scaffold but with reduced lipophilicity and shorter duration of action. Mechanism: cerebral vasodilation, modest PDE inhibition, antioxidant activity. Approved in several European countries (notably France as Pervincamine and Italy) for cerebrovascular insufficiency, mild dementia, and age-related cognitive decline. Plasma half-life is approximately 1 hour; oral bioavailability is moderate. Used as a cerebrovascular agent in academic research and as the historical reference compound for the eburnane class.

Mechanism of action

Indole alkaloid cerebral vasodilator; modest PDE inhibition. Parent natural compound of vinpocetine.

Reported research dose ranges

Clinical 30 to 60 mg in the published literature.

References

Maillard MC, et al. Pharmacology of vincamine. CNS Drug Rev 1997.
Patyar S, et al. Role of vinpocetine in cerebrovascular diseases (vincamine context). Pharmacol Rep 2011.
Cook P, James I. Cerebral vasodilators. N Engl J Med 1981.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-306

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Vincamine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs